Abstract Details

Title Echolucent Internal Carotid Artery Plaques Are Prevalent in Symptomatic Patients

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P01 - (-)

Poster/Presentation
Number 222

Objective

Background BACKGROUND: Atherosclerotic plaques in carotid arteries are responsible for 10-20% of strokes. This study assessed the relationship between ultrasonographic carotid plaque characteristics and stroke symptoms.

Design/Methods DESIGN/METHODS: We prospectively evaluated patients with 60-99 % internal carotid stenosis. Ultrasonography of the carotid arteries was performed with a 7-MHz duplex-type scanner Acuson 128XP/10C, and carotid plaque morphology (classified according to Gray-Weale classification) as well as plaque surface features were assessed.

Results RESULTS: Between July 2009 and July 2012 ,we evaluated147 patients with symptomatic carotid stenosis and 150 with asymptomatic carotid disease . There was no difference in vascular risk factor profile between both groups. Types I and II plaques were more frequent in symptomatic patients (57% versus 35% ; p < 0.002), as well as plaque ulceration (20% vs 10%; p = 0.05). Asymptomatic patients had higher prevalence of coronary disease (36 % vs 23 % p 0.01) and peripheral vascular (34% vs 19 % 0.006) disease than symptomatic ones.

Conclusions CONCLUSIONS: We found, an association between echolucent type I and II carotid plaques and symptomatic carotid disease .Further prospective studies of plaque morphology in asymptomatic patients might be useful to identify high-risk groups.

Authors/Disclosures
PRESENTER	No disclosure on file
Maulik Shah, MD (UCSF Neurology)	Dr. Shah has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for National Football League.
Maria C. Zurru, MD	No disclosure on file
	No disclosure on file
	No disclosure on file
Steven M. Greenberg, MD, PhD, FAAN	Dr. Greenberg has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bayer. Dr. Greenberg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squib. The institution of Dr. Greenberg has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alnylam. Dr. Greenberg has received research support from National Institutes of Health. Dr. Greenberg has received publishing royalties from a publication relating to health care.
Gabriela Orzuza	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Edgardo Cristiano, MD (Hospital Italiano De Buenos Aires)	Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Genzyme. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Cristiano has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck.

��ɫ��

��ɫ��